Zafgen Inc. (NASDAQ:ZFGN) Director Frances K. Heller purchased 10,000 shares of the business’s stock in a transaction on Tuesday, November 15th. The shares were bought at an average price of $3.54 per share, for a total transaction of $35,400.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at $70,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Zafgen Inc. (NASDAQ:ZFGN) opened at 3.58 on Monday. The company has a 50 day moving average price of $3.37 and a 200-day moving average price of $4.50. The firm’s market capitalization is $97.85 million. Zafgen Inc. has a 12 month low of $2.89 and a 12 month high of $18.25.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its position in shares of Zafgen by 0.9% in the third quarter. Rhumbline Advisers now owns 34,992 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 300 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Zafgen by 4.9% in the second quarter. ProShare Advisors LLC now owns 23,099 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 1,075 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of Zafgen by 25.1% in the second quarter. Alps Advisors Inc. now owns 38,312 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 7,683 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Zafgen by 33.8% in the second quarter. California State Teachers Retirement System now owns 47,925 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 12,104 shares during the last quarter. Finally, Alliancebernstein L.P. purchased a new position in shares of Zafgen during the second quarter worth $114,000. Hedge funds and other institutional investors own 65.63% of the company’s stock.

Several equities research analysts have weighed in on ZFGN shares. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Tuesday, July 26th. Cowen and Company restated a “buy” rating and set a $60.00 price target on shares of Zafgen in a report on Thursday, August 25th. Finally, FBR & Co restated a “hold” rating on shares of Zafgen in a report on Tuesday, September 20th. Five investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Zafgen presently has an average rating of “Buy” and a consensus target price of $14.22.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

5 Day Chart for NASDAQ:ZFGN

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.